@article{2210a2f22a724f2ba4990e7ba76ed180,
title = "A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study",
keywords = "Cannabinoid-1 receptor, Endocannabinoid, Randomized clinical trial, Body Mass Index, Body Weight/drug effects, Double-Blind Method, Receptor, Cannabinoid, CB1/agonists, Risk Assessment, Humans, Middle Aged, Pyridines/administration \& dosage, Male, Treatment Outcome, Diet, Reducing, Young Adult, Metabolic Syndrome/drug therapy, Anti-Obesity Agents/administration \& dosage, Aged, 80 and over, Adult, Female, Aged, Amides/administration \& dosage, Obesity/drug therapy",
author = "Aronne, \{L. J.\} and S. Tonstad and M. Moreno and I. Gantz and N. Erondu and S. Suryawanshi and C. Molony and S. Sieberts and J. Nayee and Meehan, \{A. G.\} and D. Shapiro and Heymsfield, \{S. B.\} and Kaufman, \{K. D.\} and Amatruda, \{J. M.\}",
note = "Funding Information: The study was funded by Merck \& Co. The authors IG, NE, SS, CM, SS, JN, AGM, DS, SBH, KDK and JMA are or were employees of Merck \& Co., Inc. and may hold stock in that company. LA and ST are members of a Merck Diabetes and Obesity Advisory Committee.",
year = "2010",
month = may,
doi = "10.1038/ijo.2010.21",
language = "English",
volume = "34",
pages = "919--935",
journal = "International Journal of Obesity",
issn = "0307-0565",
number = "5",
}